Ritopine Tablet combines Ritonavir 50mg and Lopinavir 200mg, two well-established protease inhibitors used in the treatment of HIV-1 infection. This fixed-dose combination is designed to provide effective viral suppression when used as part of combination antiretroviral therapy.
Lopinavir works by inhibiting the HIV protease enzyme, preventing the virus from producing mature, infectious particles. Ritonavir acts as a pharmacokinetic enhancer, increasing lopinavir plasma levels by inhibiting its metabolism, thereby improving efficacy and duration of action.
Clinically, Ritopine Tablet is indicated for adult and pediatric patients with HIV-1 infection, usually in combination with other antiretroviral medicines. The tablet formulation ensures accurate dosing, consistent bioavailability, and suitability for long-term therapy under medical supervision.
Regular use as prescribed helps in reducing viral load, improving CD4 cell counts, and slowing disease progression, contributing to better long-term health outcomes. Ritopine Tablet remains a trusted antiretroviral therapy, offering proven effectiveness in comprehensive HIV management.